Jean‐Marc Lapierre

Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists

Tara Mirzadegan, Frank Diehl, Bettina Ebi et al. · Journal of Biological Chemistry · 2000 · 248 citations · Full text

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry · 2016 · 105 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +18

Discovery and Optimization of a Series of 3-(3-Phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Mark A. Ashwell, Jean‐Marc Lapierre, Christopher J. Brassard et al. · Journal of Medicinal Chemistry · 2012 · 98 citations · Full text

Chemical Biology, Pharmaceutical Chemistry, Biophysical Screening Strategy +19

Chiral Dendrimers from Tris(hydroxymethyl)methane Derivatives

Dieter Seebàch, Jean‐Marc Lapierre, Konstantinos Skobridis et al. · Angewandte Chemie International Edition in English · 1994 · 87 citations

Type 1, Chiral Core, Organic Chemistry +6

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Terence Hall, Yi Yu, Sudharshan Eathiraj et al. · PLoS ONE · 2016 · 84 citations · Full text

Fgfr Pathway, Immunology, Cancer Biology +21